AnaBios receives IDIQ contract to assess drug safety related to cardiac function

The U.S. Food and Drug Administration (FDA) has awarded AnaBios an exclusive Indefinite Delivery Indefinite Quantity (IDIQ) contract to employ adult human primary tissues and cardiomyocytes from organ donors to assess drug safety related to cardiac function.

AnaBios is very honored to receive this contract from the FDA for this important project related to the cardiac safety assessment of drugs,

For over a decade, AnaBios has worked diligently to develop a translational ex-vivo human heart platform. We anticipate this collaboration will deliver critical data that could improve future regulatory and pharmaceutical industry decision-making."

Dr. Paul E. Miller

Miller is the co-founder and Chief Corporate Development Officer of AnaBios.

The award is a firm-fixed task order under the IDIQ, Electrophysiological and Contractility Assessment of Drugs on Primary Adult Ventricular Tissues.

This research is expected to help the FDA characterize adverse drug effects and is consistent with the FDA's mission of protecting public health by ensuring the safety and efficacy of drugs available to patients.